• Molecular NameFludarabine
  • SynonymFAMP; Fludarabine 5'-monophosphate; Fludarabine monophosphate; Fludarabine phosphate
  • Weight365.214
  • Drugbank_IDDB01073
  • ACS_NO21679-14-1
  • Show 2D model
  • LogP (experiment)-0.852
  • LogP (predicted, AB/LogP v2.0)-3.09
  • pka3.2, 5.8
  • LogD (pH=7, predicted)-7.91
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.25
  • LogSw (predicted, AB/LogsW2.0)7.71
  • Sw (mg/ml) (predicted, ACD/Labs)0.57
  • No.of HBond Donors6
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds4
  • TPSA195.88
  • StatusFDA approved
  • AdministrationIntravenous, oral
  • PharmacologyA chemotherapy drug used in the treatment of hematological malignancies.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability57.5
  • Protein binding24.0
  • Volume of distribution (VD)2.4 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFludarabine phosphate is rapidly dephosphorylated to fludarabine, after intravenous administration, and is taken up by lymphocytes where it is rephosphorylated, by kinase, to active fludarabine triphosphate (2-F-ara-ATP).
  • Half life10~30 h
  • ExcretionExcretion is mainly via the kidneys with approx. 60% of a dose being excreted in urine within 24 h. Considerable variations in pharmacokinetics have been observed between individuals.
  • Urinary Excretion24
  • Clerance3.7 ml/min/kg
  • ToxicityHigh doses of fludarabine phosphate are associated with irreversible central nervous system toxicity with symptoms such as blindness, coma and even death. Also, myelosuppression, pulmonary toxicity, ototoxicity, severe thrombocytopenia and neutropenia, owing to bone marrow suppression, have also been observed. The main intracellular metabolite, 2-F-ara-ATP, has cytotoxicity activity.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A